We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Immunoassays Rapidly Identify Cardiac Biomarkers

By LabMedica International staff writers
Posted on 03 Mar 2011
A complete battery of STAT immunoassays was introduced for cardiac biomarker testing.

The immunoassays are performed on the cobas 6000 analyzer series, an integrated system designed for diagnostic labs with medium testing volumes.

The new nine-minute STAT immunoassay tests include troponin T, creatine kinase-MB (CK-MB), myoglobin, and N-terminal pro-brain natriuretic peptide (NT-proBNP) and run on the cobas e 601 analyzer, an integrated platform that offers both clinical chemistry and immunoassay testing.

Roche (Basel, Switzerland) unveiled the STAT immunoassays for cardiac biomarker testing. The assays are faster than any other cardiac immunoassay tests currently available on an integrated platform and enable labs to deliver results to doctors treating cardiac patients in about half the time of standard Roche tests. The STAT tests are virtually equivalent to Roche's 18-minute tests in performance, precision, and sensitivity.

The cardiac STAT assays can all be run with one simple blood draw via the Roche OneTUBE solution, which consists of a single lithium heparin tube that can be run on any of Roche's integrated platforms. By allowing a single technician to process a single draw from a single point of entry instead of drawing multiple tubes for cardiac tests on multiple analyzers, the OneTUBE solution helps to simplify sample handling and reduce the need for sample splitting.

Related Links:
Roche



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics

Latest Immunology News

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
03 Mar 2011  |   Immunology

Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
03 Mar 2011  |   Immunology

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions
03 Mar 2011  |   Immunology